Acticor Biotech (France) Performance
| ALACT Stock | EUR 0.25 0.00 0.00% |
The firm shows a Beta (market volatility) of 1.04, which signifies a somewhat significant risk relative to the market. Acticor Biotech returns are very sensitive to returns on the market. As the market goes up or down, Acticor Biotech is expected to follow. At this point, Acticor Biotech SAS has a negative expected return of -0.41%. Please make sure to confirm Acticor Biotech's jensen alpha and kurtosis , to decide if Acticor Biotech SAS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Acticor Biotech SAS has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Begin Period Cash Flow | 7.6 M | |
| Total Cashflows From Investing Activities | -12 K |
Acticor |
Acticor Biotech Relative Risk vs. Return Landscape
If you would invest 39.00 in Acticor Biotech SAS on October 20, 2024 and sell it today you would lose (14.00) from holding Acticor Biotech SAS or give up 35.9% of portfolio value over 90 days. Acticor Biotech SAS is generating negative expected returns and assumes 7.8298% volatility on return distribution over the 90 days horizon. Simply put, 69% of stocks are less volatile than Acticor, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Acticor Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acticor Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acticor Biotech SAS, and traders can use it to determine the average amount a Acticor Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0518
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALACT |
Estimated Market Risk
| 7.83 actual daily | 69 69% of assets are less volatile |
Expected Return
| -0.41 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Acticor Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acticor Biotech by adding Acticor Biotech to a well-diversified portfolio.
Acticor Biotech Fundamentals Growth
Acticor Stock prices reflect investors' perceptions of the future prospects and financial health of Acticor Biotech, and Acticor Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acticor Stock performance.
| Return On Equity | -3.33 | |||
| Return On Asset | -0.69 | |||
| Current Valuation | 76.26 M | |||
| Shares Outstanding | 10.52 M | |||
| Price To Earning | 35.47 X | |||
| Price To Book | 18.24 X | |||
| Price To Sales | 5.71 X | |||
| EBITDA | (11.92 M) | |||
| Cash And Equivalents | 571.18 K | |||
| Cash Per Share | 0.17 X | |||
| Total Debt | 2.2 M | |||
| Debt To Equity | 662.10 % | |||
| Book Value Per Share | 0.41 X | |||
| Cash Flow From Operations | (13.75 M) | |||
| Earnings Per Share | (1.34) X | |||
| Total Asset | 17.88 M | |||
About Acticor Biotech Performance
Assessing Acticor Biotech's fundamental ratios provides investors with valuable insights into Acticor Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Acticor Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Acticor Biotech SAS, a clinical stage biopharmaceutical company, develops drugs for the treatment of acute phase of thrombotic diseases. The company was founded in 2013 and is headquartered in Paris, France. ACTIPLAY is traded on Paris Stock Exchange in France.Things to note about Acticor Biotech SAS performance evaluation
Checking the ongoing alerts about Acticor Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acticor Biotech SAS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acticor Biotech SAS generated a negative expected return over the last 90 days | |
| Acticor Biotech SAS has high historical volatility and very poor performance | |
| Acticor Biotech SAS has some characteristics of a very speculative penny stock | |
| Acticor Biotech SAS has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (12.61 M) with profit before overhead, payroll, taxes, and interest of 320.18 K. | |
| Acticor Biotech SAS has accumulated about 571.18 K in cash with (13.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17. |
- Analyzing Acticor Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acticor Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Acticor Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acticor Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acticor Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acticor Biotech's stock. These opinions can provide insight into Acticor Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Acticor Stock Analysis
When running Acticor Biotech's price analysis, check to measure Acticor Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acticor Biotech is operating at the current time. Most of Acticor Biotech's value examination focuses on studying past and present price action to predict the probability of Acticor Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acticor Biotech's price. Additionally, you may evaluate how the addition of Acticor Biotech to your portfolios can decrease your overall portfolio volatility.